The Bristol-Myers Squibb Co. (BMY) Position Increased by Mn Services Vermogensbeheer B.V.

The Bristol-Myers Squibb Co. (BMY) Position Increased by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. raised its stake in Bristol-Myers Squibb Co. (NYSE:BMY) by 1.9% during the third quarter, Holdings Channel reports. The institutional investor owned 43,185 shares of the biopharmaceutical company’s stock after buying an additional 812 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Bristol-Myers Squibb were worth $2,329,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the company. Vanguard Group Inc. increased its stake in Bristol-Myers Squibb by 3.4% in the second quarter. Vanguard Group Inc. now owns 109,554,831 shares of the biopharmaceutical company’s stock valued at $8,057,758,000 after buying an additional 3,595,648 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in Bristol-Myers Squibb by 5.7% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 46,977,248 shares of the biopharmaceutical company’s stock valued at $2,533,013,000 after buying an additional 2,517,496 shares in the last quarter. BlackRock Fund Advisors increased its stake in Bristol-Myers Squibb by 2.4% in the third quarter. BlackRock Fund Advisors now owns 24,360,986 shares of the biopharmaceutical company’s stock valued at $1,313,544,000 after buying an additional 580,043 shares in the last quarter. Janus Capital Management LLC increased its stake in Bristol-Myers Squibb by 5.2% in the second quarter. Janus Capital Management LLC now owns 21,937,539 shares of the biopharmaceutical company’s stock valued at $1,613,481,000 after buying an additional 1,094,167 shares in the last quarter. Finally, BlackRock Group LTD increased its stake in Bristol-Myers Squibb by 2.5% in the third quarter. BlackRock Group LTD now owns 14,942,065 shares of the biopharmaceutical company’s stock valued at $805,676,000 after buying an additional 365,557 shares in the last quarter. Institutional investors and hedge funds own 68.89% of the company’s stock.

Shares of Bristol-Myers Squibb Co. (NYSE:BMY) traded down 1.03% during trading on Thursday, hitting $55.49. 6,890,903 shares of the company were exchanged. The stock has a market capitalization of $92.74 billion, a PE ratio of 27.76 and a beta of 0.94. The company has a 50 day moving average of $57.82 and a 200-day moving average of $59.28. Bristol-Myers Squibb Co. has a 1-year low of $49.03 and a 1-year high of $77.12.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.12. Bristol-Myers Squibb had a return on equity of 28.98% and a net margin of 18.54%. The business had revenue of $4.83 billion for the quarter, compared to the consensus estimate of $4.76 billion. During the same quarter in the previous year, the company posted $0.39 EPS. The company’s revenue was up 21.0% compared to the same quarter last year. On average, analysts forecast that Bristol-Myers Squibb Co. will post $2.86 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 1st. Stockholders of record on Friday, January 6th will be given a dividend of $0.39 per share. The ex-dividend date is Wednesday, January 4th. This represents a $1.56 annualized dividend and a dividend yield of 2.81%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.38. Bristol-Myers Squibb’s payout ratio is currently 76.47%.

A number of research analysts have recently issued reports on BMY shares. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, January 9th. Jefferies Group restated a “buy” rating and issued a $69.00 price target on shares of Bristol-Myers Squibb in a research report on Thursday, January 5th. BMO Capital Markets dropped their price target on shares of Bristol-Myers Squibb from $60.00 to $56.00 and set a “market perform” rating on the stock in a research report on Monday, October 24th. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $58.77 price target on the stock. in a research report on Monday, November 7th. Finally, Citigroup Inc. restated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, November 8th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $65.89.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).

Related posts

Leave a Comment